WEKO3
アイテム
Carbon Ion Radiotherapy in Hypofraction Regimen for Stage I Non-Small Cell Lung Cancer
https://repo.qst.go.jp/records/61947
https://repo.qst.go.jp/records/6194719de117a-3fc1-49c9-80e1-b0111ac2beec
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2006-12-07 | |||||
| タイトル | ||||||
| タイトル | Carbon Ion Radiotherapy in Hypofraction Regimen for Stage I Non-Small Cell Lung Cancer | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Miyamoto, Tadaaki
× Miyamoto, Tadaaki× Baba, Masayuki× Yashiro, Tomoyasu× Sugane, Toshio× Nakajima, Mio× Tsujii, Hirohiko× 宮本 忠昭× 馬場 雅行× 矢代 智康× 須金 紀雄× 中嶋 美緒× 辻井 博彦 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | From 1994 to 1999, we conducted a phase I/II clinical trial for stage I non-small cell lung cancer (NSCLC) by using carbon ion beams alone, demonstrating optimal doses of 90 GyE in 18 fractions over 6 weeks and 72 GyE in 9 fractions over 3 weeks for achieving more than 95% local control with minimal pulmonary damage. In the present study, the total dose was fixed at 72 GyE in 9 fractions over 3 weeks, and at 52.8 GyE for stage IA and 60 GyE for stage 1B in 4 fractions over 1 week. Following this schedule, we conducted a phase II clinical trial for stage I NSCLC from 1999 to 2003. Most targets were irradiated from four oblique directions. A respiratory-gated irradiation system was used for all sessions. Local control and survival were assessed by the Kaplan-Meier method. For statistical testing, the long-rank test was used. The local control rate for all patients was 91.5%, and those for T1 and T2 tumors were 96.3% and 84.7%, respectively. While there was significant difference (p=0.0156) in tumor control rate between T1 and T2, there was no significant difference (P=0.1516) between squamous and non-squamous. The five-year cause-specific survival rate was 67.0% (IA: 84.4, IB: 43.7), and overall survival was 45.3% (IA: 53.9, 1B: 34.2). No adverse effects greater than grade 3 occurred in the lung. Carbon beam radiotherapy, an excellent new modality in terms of high QOL and ADL, was proven to be a valid alternative to surgery for stage I cancer, especially for elderly and inoperable patients. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | NIRS-CNAO Joint Symposium on Carbon Ion Radiotherapy | |||||
| 発表年月日 | ||||||
| 日付 | 2006-11-28 | |||||
| 日付タイプ | Issued | |||||
